The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price gain of 2682.33% this year. Over the last six months, there has been a weaker performance of 3050.93%. The price of AVTE fallen by 2837.52% during the last 30 days period. For the last 5-days stocks have slided -0.56%.
The market performance of Aerovate Therapeutics Inc’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $2.86 on 06/14/24, while the lowest value for the same duration was $0.05 on 06/20/24.
52-week price history of AVTE Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Aerovate Therapeutics Inc’s current trading price is -6.82% away from its 52-week high, while its distance from the 52-week low is 5798.53%. The stock’s price range during this period has varied between$0.05 and $2.86. The Aerovate Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.86 million for the day, a figure considerably higher than their average daily volume of 2.67 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Aerovate Therapeutics Inc (AVTE) has experienced a quarterly rise of 2780.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 77.25M and boasts a workforce of 30 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.55, with a change in price of -0.01. Similarly, Aerovate Therapeutics Inc recorded 221,362 in trading volume during the last 100 days, posting a change of -0.37%.
AVTE’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AVTE stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
AVTE Stock Stochastic Average
Aerovate Therapeutics Inc’s raw stochastic average for the past 50 days is presently 69.35%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 53.66%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 66.67% and 74.18%, respectively.
